MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $485 from $483 and keeps an Outperform rating on the shares ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union <li /> Conditional marketing au ...

Madrigal Pharmaceuticals has secured conditional marketing authorization for Rezdiffra, its treatment for a serious liver condition, from regulators in Europe. The biopharmaceutical company said ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.